Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
HP Version - Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
Optimise reading forHealth ProfessionalsPatients
Closed (no longer recruiting)Last updated: 15 January 2024
Clinical summaryEligibilityParticipating hospitalsSupport
This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) or small lymphocytic lymphoma (SLL) and evaluate the overall safety profile of idelalisib and the overall response rate (ORR) by Week 24.
This trial is treating patients with Follicular Lymphoma.
Haematological
18+
III
Idelalisib
Use the hyperlinks, where available to access additional clinical trial information.
Gilead Sciences, Inc.
Dose Optimization Study of Idelalisib in Follicular Lymphoma or Small Lymphocytic Lymphoma
Share with email
Print this page
Download brochure
Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trials have complex eligibility criteria.
Ask your doctor if this trial could be right for you.
+ Show non-recruiting hospitals
Tell us if you find this trial availability is not accurate.Report inaccuracy
Speak with someone who has cancer clinical trial experience.
Learn more
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.